Irritable bowel syndrome therapy in Vietnam with probiotic enterococci

Ermolenko, E. I.; Kotyleva, M. P.; Tsapieva, Anna N.; Karaseva, Alena; Bui, Thi Lan An; Suvorov, Alexander

doi:10.31146/1682-8658-ecg-196-12-35-43

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correction of dysbiosis was accompanied by a stimulation of anti-inflammatory cytokines IL-10, TGF-β, and a reduction in proinflammatory cytokines MCP1 and IL-8 [35]. The same model shows a beneficial effect of autoprobiotics on intestinal motility [70]. Also, we demonstrated that autoprobiotic intake contributes to a decrease in dyspeptic symptoms and is associated with positive changes in the gut microbiota content [71,72], as well as the vaginal microbiota content [73].…”

Section: Discussionsupporting

confidence: 67%

See 1 more Smart Citation

Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period

Ermolenko,

Baryshnikova,

Alekhina

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Despite great advances in the treatment of oncological diseases, the development of medical technologies to prevent or reduce complications of therapy, in particular, those associated with surgery and the introduction of antibiotics, remains relevant. The aim of this study is to evaluate the effectiveness of the use of autoprobiotics based on indigenous non-pathogenic strains of Enterococcus faecium and Enterococcus hirae as a personalized functional food product (PFFP) in the complex therapy of colorectal cancer (CRC) in the early postoperative period. A total of 36 patients diagnosed with CRC were enrolled in the study. Study group A comprised 24 CRC patients who received autoprobiotic therapy in the early postoperative period, while the control group C included 12 CRC patients without autoprobiotic therapy. Prior to surgery and between days 14 and 16 post-surgery, comprehensive evaluations were conducted on all patients, encompassing the following: stool and gastroenterological complaints analysis, examination of the gut microbiota (bacteriological study, quantitative polymerase chain reaction, metagenome analysis), and analysis of interleukins in the serum. Results: The use of autoprobiotics led to a decrease in dyspeptic complaints after surgery. It was also associated with the absence of postoperative complications, did not cause any side effects, and led to a decrease in the level of pro-inflammatory cytokines (IL-6 and IL-18) in the blood serum. The use of autoprobiotics led to positive changes in the structure of escherichia and enterococci populations, the elimination of Parvomonas micra and Fusobacterium nucleatum, and a decrease in the quantitative content of Clostridium perfringens and Akkermansia muciniphila. Metagenomic analysis (16S rRNA) revealed an increase in alpha diversity. Conclusion: The introduction of autoprobiotics in the postoperative period is a highly effective and safe approach in the complex treatment of CRC. Future studies will allow the discovery of additional fine mechanisms of autoprobiotic therapy and its impact on the digestive, immune, endocrine, and neural systems.

show abstract

Section: Discussionsupporting

confidence: 67%

“…A special feature of this study was the additional use of E. hirae, which we first discovered as candidates for autoprobiotic agents in Vietnam [80,81], and after that, in Russia for patients with CRC.…”

Section: Discussionmentioning

confidence: 99%

Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period

Ermolenko,

Baryshnikova,

Alekhina

et al. 2024

Microorganisms

View full text Add to dashboard Cite

show abstract

Probiotic consortiums: Structure and antagonistic activity against opportunistic bacteria and human normobiota (using the example of <i>Escherichia coli</i>) <i>in vitro</i>

Pendyukhova,

Belkova,

Savinova

et al. 2023

Acta biomedica scientifica

View full text Add to dashboard Cite

Background. Using probiotic preparations based on consortia of microorganisms not only helps to restore the balance of the intestinal microbiota, but also increases the therapeutic effect of probiotics. Promising sources for obtaining probiotic consortia are milk products that have undergone natural fermentation with the help of spontaneously formed microbial consortia. The aim. To study the structure of five microbial consortia with probiotic properties from naturally fermented milk products and to assess in vitro their antagonistic activity against opportunistic bacteria and a representative of the human normobiota – Escherichia coli. Materials and methods. The structure of bacterial consortia was analyzed by sequencing methods. The antagonistic activity of the consortia was assessed by the disk diffusion method. Results. It has been established that the studied microbial consortiums are represented by Enterococcus spp. and Streptococcus spp. bacteria. In consortiums No. 1, No. 2, and No. 3, Enterococcus bacteria dominated, while in consortiums No. 4 and No. 5, Streptococcus dominated. Antagonistic activity was shown against four isolates of opportunistic bacteria: Klebsiella pneumoniae No. 493, Enterobacter hormaechei No. 372, Staphylococcus aureus No. 4 and Pseudomonas aeruginosa No. 25 IMB, as well as against one representative of the human normobiota – Escherichia coli No. 495. The highest growth delay zone is found in E. coli No. 495 isolate. Three test cultures (K. pneumoniae No. 509, E. coli ATCC25922 and P. aeruginosa No. 3 IMB) exhibited more dense growth around probiotic consortia. Conclusion. The results of the study showed that the effect of probiotic consortia differing in the composition of microorganisms can be neutral and bactericidal. The presence of antagonistic activity in the studied microbial consortia against multiresistant isolates of opportunistic bacteria is a prospect for creating probiotics with antibacterial properties.

show abstract

Evaluation of the effectiveness of personalised therapy for the patients with irritable bowel syndrome

Ermolenko

Ситкин

Vakhitov

et al. 2023

View full text Add to dashboard Cite

Intestinal microbiota correction in the therapy of irritable bowel syndrome (IBS) is an important medical problem. We conducted a laboratory and pilot clinical trial to investigate the effect of autoprobiotic bacteria, indigenous bifidobacteria and enterococci isolated from faeces and grown on artificial media to use as personified food additives in IBS treatment. Convincing evidence of the clinical efficacy of autoprobiotic was demonstrated by the disappearance of dyspeptic symptoms. The microbiome of patients with IBS was compared to a group of healthy volunteers and changes in the microbiome after autoprobiotic use were detected by quantitative polymerase chain reaction and 16S rRNA metagenome analysis. The possibility of reducing opportunistic microorganisms in the treatment of IBS with autoprobiotics has been convincingly proven. The quantitative content of enterococci in the intestinal microbiota was higher in IBS patients than in healthy volunteers and increased after therapy. An increase in the relative abundance of genera Coprococcus, Blautia and a decrease in the relative abundance of Paraprevotella spp. were found at the end of therapy. A metabolome study which was performed by gas chromatography and mass spectrometry demonstrated an increase in the content of oxalic acid, a decrease of dodecanoate, lauric acid, and other metabolome components after taking autoprobiotics. Some of these parameters correlated with the relative abundances of Paraprevotella spp., Enterococcus spp., and Coprococcus spp. representative of the microbiome. Apparently, they reflected the peculiarities of metabolic compensation and changes in the microbiota. Therefore, the use of autoprobiotics for treatment of IBS may lead to a stable positive clinical effect, associated with compensatory changes in the intestinal microbiota, and accompanied by corresponding changes in metabolic processes in the organism.

show abstract

Irritable bowel syndrome therapy in Vietnam with probiotic enterococci

Cited by 3 publications

References 27 publications

Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period

Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period

Probiotic consortiums: Structure and antagonistic activity against opportunistic bacteria and human normobiota (using the example of <i>Escherichia coli</i>) <i>in vitro</i>

Evaluation of the effectiveness of personalised therapy for the patients with irritable bowel syndrome

Contact Info

Product

Resources

About